MAP2K7 and neuroblastoma: Interestingly, individual studies in SCLC or neuroblastoma have also reported many of these associations, such as MEK inhibitors for neuroblastoma (62), HSP90 inhibitors for SCLC (63) and neuroblastoma (64), and BCL2 inhibitors for SCLC (65) and neuroblastoma (66).